7.58
-0.53 (-6.54%)
| Previous Close | 8.11 |
| Open | 8.01 |
| Volume | 90,202 |
| Avg. Volume (3M) | 268,022 |
| Market Cap | 195,608,704 |
| Price / Earnings (Forward) | 11.78 |
| Price / Sales | 2.84 |
| Price / Book | 2.54 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | -42.99% |
| Operating Margin (TTM) | -76,248.27% |
| Diluted EPS (TTM) | -2.87 |
| Quarterly Revenue Growth (YOY) | -99.80% |
| Total Debt/Equity (MRQ) | 60.30% |
| Current Ratio (MRQ) | 6.62 |
| Operating Cash Flow (TTM) | -58.52 M |
| Levered Free Cash Flow (TTM) | 6.86 M |
| Return on Assets (TTM) | -17.83% |
| Return on Equity (TTM) | -50.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Precision BioSciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.94% |
| % Held by Institutions | 42.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aberdeen Group Plc | 31 Mar 2026 | 2,230,178 |
| Empery Asset Management, Lp | 31 Mar 2026 | 1,968,879 |
| Octagon Capital Advisors Lp | 31 Dec 2025 | 1,917,995 |
| Bleichroeder Lp | 31 Mar 2026 | 1,662,500 |
| Boothbay Fund Management, Llc | 31 Dec 2025 | 1,066,050 |
| Driehaus Capital Management Llc | 31 Mar 2026 | 995,371 |
| Lynx1 Capital Management Lp | 31 Mar 2026 | 985,113 |
| Alyeska Investment Group, L.P. | 31 Dec 2025 | 798,000 |
| Affinity Asset Advisors, Llc | 31 Mar 2026 | 597,946 |
| Sphera Funds Management Ltd. | 31 Dec 2025 | 396,116 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |